MSI-H Cancer clinical trials at UCSF
1 research study open to eligible people
MSI-H cancer is a cancer with lots of genetic changes. UCSF is running a trial to test a new IL-2 therapy for safety and early signs of effectiveness. The study involves different doses to find the best one.
Showing trials for
Beta-only IL-2 ImmunoTherapY Study
open to eligible people ages 18 years and up
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.
San Francisco, California and other locations
Last updated: